Recent clinical studies of patients with COVID-19 have not identified a clear relationship between ACE inhibitor use or ARB use and disease risk or severity (Baral et al., 2021; Bavishi et al., 2021; Morales et al., 2021), and current guidelines support continuance of ACE inhibitors or ARB during infection (Cohen et al., 2021; Lopes et al., 2021). The gene discussed is ACE; the disease is infection.